Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 30

Results For "Pharma"

3718 News Found

Briefs: Lupin and Aurobindo Pharma
News | May 13, 2024

Briefs: Lupin and Aurobindo Pharma

Lupin updates on shipment of Mirabegron ER Tablets


Piramal Pharma posts Q1 FY24 consolidated PAT at Rs. 101.27 Cr
News | May 11, 2024

Piramal Pharma posts Q1 FY24 consolidated PAT at Rs. 101.27 Cr

Piramal Pharma has reported total income of Rs. 2,578.74 crores during the period ended March 31, 2024


Alembic Pharmaceuticals receives 5 USFDA product approvals in Q1 FY25
Drug Approval | May 10, 2024

Alembic Pharmaceuticals receives 5 USFDA product approvals in Q1 FY25

Receives 3 final and 2 tentative product approvals thus far in Q1FY25


Alembic Pharmaceuticals posts Q4 FY24 PAT at Rs. 178.21 Cr
News | May 10, 2024

Alembic Pharmaceuticals posts Q4 FY24 PAT at Rs. 178.21 Cr

The company has posted net profit of Rs.615.82 crores for the Financial Year ended March 31, 2024


Piramal Pharma launches new campaign for 'Polycrol' with Brand Ambassador Jisshu Sengupta
News | May 09, 2024

Piramal Pharma launches new campaign for 'Polycrol' with Brand Ambassador Jisshu Sengupta

the campaign emphasizes the brand's reliability and effectiveness in providing timely relief


Gland Pharma receives approval for Edaravone Injection
Drug Approval | May 09, 2024

Gland Pharma receives approval for Edaravone Injection

The product is used to treat amyotrophic lateral sclerosis


WACKER expands production capacity for biopharmaceuticals in San Diego
News | May 08, 2024

WACKER expands production capacity for biopharmaceuticals in San Diego

Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA


Alembic Pharmaceuticals receives EIR from USFDA for oncology formulation facility
Drug Approval | May 07, 2024

Alembic Pharmaceuticals receives EIR from USFDA for oncology formulation facility

With this, for all our USFDA facilities, EIRs are in place


Briefs: Eugia Pharma Specialities and IOL Chemicals and Pharmaceuticals
Drug Approval | May 06, 2024

Briefs: Eugia Pharma Specialities and IOL Chemicals and Pharmaceuticals

Eugia Pharma Specialities receives 7 observations from USFDA for Unit II


Tatva Chintan Pharma Chem posts Q4 FY24 PAT at Rs. 9.61 Cr
News | May 06, 2024

Tatva Chintan Pharma Chem posts Q4 FY24 PAT at Rs. 9.61 Cr

The company has posted net profit of Rs.30.35 crores for the Financial Year ended March 31, 2024